ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 494

Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice

Dmitry Karayev1, Guoqiu Shen1, Yvonne Lam1, Andrew Rimmer1, Nayan Lal1, Eugene Karayev1, Kristine Azarraga1, Ronald A. Blum1, Allan L. Metzger1, Robert I. Morris1 and Arash A. Horizon2, 1Rheumatology Diagnostics Laboratory, Inc. (RDL), Los Angeles, CA, 2Center for Rheumatology Medical Group, Los Angeles, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: anti-CCP antibodies, Diagnostic Tests, rheumatoid arthritis (RA) and serologic tests, Rheumatoid Factor

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: RA is the most common autoimmune inflammatory joint disease, affecting up to 1% of the world population. Detection of antibodies, specifically against IgM rheumatoid factor (IgM-RF) and anti-cyclic citrullinated peptide (anti-CCP) is widely used for the diagnosis of RA; both of these antibodies are included in the 2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria. However, novel antibodies have been identified that can help further diagnose seronegative (IgM-RF and anti-CCP negative) RA patients. In addition to antibodies targeting cyclic citrullinated peptide (CCP), antibodies to citrullinated alpha-enolase peptide 1 (CEP-1) and citrullinated vimentin (Sa) have been found in RA synovium and serum. 14-3-3η is a protein also found in high levels in synovial fluid and serum of RA patients. The purpose of this study is to examine the sensitivity and specificity of 14-3-3η, anti-CEP-1 and anti-Sa antibodies in a cohort of seronegative RA and suspected RA patients.

Methods: The 3 assays were analyzed by enzyme-linked immunosorbent assay (ELISA) in serum from a community rheumatology practice in Los Angeles, CA (USA) using 176 samples of which, 130 were established RA patients and 46 suspected RA patients.  Specificity was tested using 20 SLE, 16 psoriatic arthritis, 12 Sjogren’s Syndrome and 20 Non-Rheumatic Disease Patient (NRDP) samples. Levels of 14-3-3η (Augurex Life Sciences Corp.), anti-CEP-1 and anti-Sa antibodies (Euroimmun) where measured using a laboratory developed test (LDT) at Rheumatology Diagnostics Laboratory, Inc. (RDL). Levels of anti-CCP IgG/IgA and IgM-RF were obtained on all serum samples.           

Results: Out of 130 established RA patients, 50 (38%) were seronegative for both IgM-RF and anti-CCP antibodies. Of these 50 seronegative patients, 14-3-3η was positive in 5 patients (10%), while anti-CEP-1 and/or anti-Sa antibodies were positive in 5 additional patients (10%). Out of the 46 suspected RA patients, 38 (83%) were seronegative for both IgM-RF and anti-CCP antibodies. Of these 38 seronegative suspected RA patients, 14-3-3η was positive in 4 patients (11%), while no anti-CEP-1 or anti-Sa antibodies were positive.  

Conclusion:    In an established RA cohort negative for both IgM-RF and anti-CCP antibodies, further testing for 14-3-3η, anti-CEP-1 and anti-Sa antibodies identified an additional 20% of RA patients. In suspected RA patients (seronegative), 14-3-3η was positive in an additional 11%. The overall specificity of the 3 markers was 85%. In the autoimmune disease controls, most of the patients that tested positive for these antibodies had inflammatory arthritis/active synovitis, and therefore may have had an overlap syndrome.        


Disclosure: D. Karayev, RDL, 3; G. Shen, RDL, 3; Y. Lam, RDL, 3; A. Rimmer, RDL, 3; N. Lal, RDL, 3; E. Karayev, RDL, 3; K. Azarraga, RDL, 3; R. A. Blum, RDL, 3; A. L. Metzger, RDL, 4; R. I. Morris, RDL, 4; A. A. Horizon, None.

To cite this abstract in AMA style:

Karayev D, Shen G, Lam Y, Rimmer A, Lal N, Karayev E, Azarraga K, Blum RA, Metzger AL, Morris RI, Horizon AA. Sensitivity and Specificity of 14-3-3η, Anti-CEP-1 and Anti-Sa Antibodies in a Cohort of Seronegative and Suspected Rheumatoid Arthritis (RA) Patients from a Community Rheumatology Practice [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/sensitivity-and-specificity-of-14-3-3%ce%b7-anti-cep-1-and-anti-sa-antibodies-in-a-cohort-of-seronegative-and-suspected-rheumatoid-arthritis-ra-patients-from-a-community-rheumatology-practice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sensitivity-and-specificity-of-14-3-3%ce%b7-anti-cep-1-and-anti-sa-antibodies-in-a-cohort-of-seronegative-and-suspected-rheumatoid-arthritis-ra-patients-from-a-community-rheumatology-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology